Langer-Gould A - Search Results

1

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Langer-Gould A, et al. N Engl J Med. 2005 Jul 28;353(4):375-81. doi: 10.1056/NEJMoa051847. Epub 2005 Jun 9. N Engl J Med. 2005. PMID: 15947078 Free article.

2

Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.

Adalsteinsson E, Langer-Gould A, Homer RJ, Rao A, Sullivan EV, Lima CA, Pfefferbaum A, Atlas SW. Adalsteinsson E, et al. AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1941-5. AJNR Am J Neuroradiol. 2003. PMID: 14625214 Free PMC article.

3

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Langer-Gould A, Steinman L. Langer-Gould A, et al. Curr Neurol Neurosci Rep. 2006 May;6(3):253-8. doi: 10.1007/s11910-006-0013-z. Curr Neurol Neurosci Rep. 2006. PMID: 16635435 Review.

4

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. Hauser SL, et al. N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383. N Engl J Med. 2008. PMID: 18272891 Free article. Clinical Trial.

5

What went wrong in the natalizumab trials?

Langer-Gould A, Steinman L. Langer-Gould A, et al. Lancet. 2006 Mar 4;367(9512):708-10. doi: 10.1016/S0140-6736(06)68279-2. Lancet. 2006. PMID: 16517256 No abstract available.

6

Natalizumab use during the third trimester of pregnancy.

Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, Kümpfel T, Meinl I, Plavina T, Gold R, Hellwig K. Haghikia A, et al. JAMA Neurol. 2014 Jul 1;71(7):891-5. doi: 10.1001/jamaneurol.2014.209. JAMA Neurol. 2014. PMID: 24821217 Review.

7

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.

Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM. Langer-Gould A, et al. Arch Neurol. 2006 Dec;63(12):1686-91. doi: 10.1001/archneur.63.12.1686. Arch Neurol. 2006. PMID: 17172607 Review.

8

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Luna G, et al. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. JAMA Neurol. 2020. PMID: 31589278 Free PMC article.

9

Strategies for managing the side effects of treatments for multiple sclerosis.

Langer-Gould A, Moses HH, Murray TJ. Langer-Gould A, et al. Neurology. 2004 Dec 14;63(11 Suppl 5):S35-41. doi: 10.1212/wnl.63.11_suppl_5.s35. Neurology. 2004. PMID: 15596735 Review.

10

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.

Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Lock C, et al. Nat Med. 2002 May;8(5):500-8. doi: 10.1038/nm0502-500. Nat Med. 2002. PMID: 11984595

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page